Benzinga | Aug 6, 2021 04:20PM EDT

Qiagen's COVID-19 Antigen Test Gets FDA Emergency Use Approval

* The FDA has granted emergency use authorization (EUA) to Qiagen N.V.'s (NYSE:QGEN) QIAreach SARS CoV-2 Antigen Test.

* The rapid, portable test can detect COVID-19 antigen in people with active infections in 2 to 15 minutes.

* The test can process an average of around 30 swab samples per hour, providing digital test results that do not require subjective interpretation.

* The QIAreach test is the second Qiagen COVID-19 test to use the digital eHub and eStick system developed in partnership with Australian digital diagnostics company, Ellume.

* Lab professionals will now be able to run tests to detect both previous and active infections on one device simultaneously, with each testing slot operating independently of the others.

* Each Digital eHub device, with a capacity for up to 8 eSticks, can simultaneously run QIAreach COVID-19 antigen and antibody tests.

* Related: Qiagen Stock Gains As Non-COVID Sales Boosts Q2 Topline, Bottom-line.

* Price Action: QGEN shares closed down 0.72% at $52.36 on Friday.

* Related content: Benzinga's Full FDA Calendar.

* Photo by Mufid Majnun on Unsplash